CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, C.
Right arrow Articles by Goodman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, C.
Right arrow Articles by Goodman, G.
Related Collections
Right arrowCommentary
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 1033-1040, October 2002
© 2002 American Association for Cancer Research

Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer1

Chu Chen2, Najib Lamharzi, Noel S. Weiss, Ruth Etzioni, Douglas A. Dightman, Matt Barnett, Dante DiTommaso and Gary Goodman

Program in Epidemiology [C. C., N. L., N. S. W., D. A. D.], Cancer Prevention Program [M. B., G. G.], and Program in Biostatistics [R. E., D. D.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024; Departments of Biostatistics [R. E.] and Epidemiology [C. C., N. S. W.], University of Washington, Seattle, Washington, 98195; and Swedish Tumor Institute, Seattle, Washington 98104 [G. G.]

The human androgen receptor gene contains polymorphic CAG and GGC repeats in exon 1. We investigated whether the number of CAG and/or GGC repeats is related to prostate cancer risk in a case-control study nested within the ß Carotene and Retinol Efficacy Trial. Among 300 cases and 300 controls, we did not observe any increase in risk associated with fewer CAG or GGC repeats. We observed a nonsignificant decrease in risk associated with each unit of decrease in CAG length [odds ratio (OR), 0.98; 95% confidence interval (CI), 0.93–1.03). Men with CAG <22 had a relative risk of prostate cancer of 0.89 (95% CI, 0.65–1.23) compared with men with CAG >=22. There was no appreciable difference in the mean number of GGC repeats between cases and controls; the estimated change in the risk of prostate cancer associated with one fewer GGC repeat was 0.97 (95% CI, 0.88–1.06). The risk in men at or below the mean number of GGC repeats (17) was 0.80 (95% CI, 0.57–1.12). In contrast to prior reports, men with both short CAG (<22) and short GGC (<=17) repeats were not at increased risk of prostate cancer (OR, 0.56; 95% CI, 0.32–0.98), compared with men with >=22 CAG repeats and >17 GGC repeats. Our results do not support the hypothesis that a small number of CAG or GGC repeats in the androgen receptor gene increases a man’s risk of prostate cancer.


Commentary

Is the Androgen Receptor CAG Repeat Length Significant for Prostate Cancer? : Commentary re: C. Chen et al., Androgen Receptor Polymorphisms and the Incidence of Prostate Cancer. Cancer Epidemiol. Biomark. Prev., 11: 1033–1040, 2002
Edward Giovannucci
Cancer Epidemiol. Biomarkers Prev. 2002 11: 985-986. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
M. A. Albertelli, A. Scheller, M. Brogley, and D. M. Robins
Replacing the Mouse Androgen Receptor with Human Alleles Demonstrates Glutamine Tract Length-Dependent Effects on Physiology and Tumorigenesis in Mice
Mol. Endocrinol., June 1, 2006; 20(6): 1248 - 1260.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. A. Platz, M. F. Leitzmann, N. Rifai, P. W. Kantoff, Y.-C. Chen, M. J. Stampfer, W. C. Willett, and E. Giovannucci
Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1262 - 1269.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. M. Hayes, G. Severi, S. A. Eggleton, E. J.D. Padilla, M. C. Southey, R. L. Sutherland, J. L. Hopper, and G. G. Giles
The E211 G>A Androgen Receptor Polymorphism Is Associated with a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 993 - 996.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Ferlin, A. Garolla, A. Bettella, L. Bartoloni, C. Vinanzi, A. Roverato, and C. Foresta
Androgen receptor gene CAG and GGC repeat lengths in cryptorchidism
Eur. J. Endocrinol., March 1, 2005; 152(3): 419 - 425.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer
How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk?
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
A. Ferlin, L. Bartoloni, G. Rizzo, A. Roverato, A. Garolla, and C. Foresta
Androgen receptor gene CAG and GGC repeat lengths in idiopathic male infertility
Mol. Hum. Reprod., June 1, 2004; 10(6): 417 - 421.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Chen, N. S. Weiss, F. Z. Stanczyk, S. K. Lewis, D. DiTommaso, R. Etzioni, M. J. Barnett, and G. E. Goodman
Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1410 - 1416.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.